Last reviewed · How we verify
Placebo for Oral IR-LD/CD
This drug is a placebo, meaning it has no active therapeutic effect.
At a glance
| Generic name | Placebo for Oral IR-LD/CD |
|---|---|
| Also known as | Placebo for IR-LD/CD |
| Sponsor | NeuroDerm Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease. Placebos are often used as a control group in clinical trials to compare the efficacy of active treatments.
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Oral IR-LD/CD CI brief — competitive landscape report
- Placebo for Oral IR-LD/CD updates RSS · CI watch RSS
- NeuroDerm Ltd. portfolio CI